Targets › HA2
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Jun 2028.
Unconventional myosin required during immune response for detection of rare antigen-presenting cells by regulating T-cell migration. Unconventional myosins are actin-based motor molecules with ATPase activity and serve in intracellular movements. (UniProt, B0I1T2)
Open in Phaseline: the race on HA2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| TScan Therapeutics | TSC-101 T-cell receptor engineered donor T cells targeting HA-2 | HA2 | Phase 3 | AML | Jun 2028 |
AML (2)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.